664 related articles for article (PubMed ID: 12415308)
1. The immunology of susceptibility and resistance to Leishmania major in mice.
Sacks D; Noben-Trauth N
Nat Rev Immunol; 2002 Nov; 2(11):845-58. PubMed ID: 12415308
[TBL] [Abstract][Full Text] [Related]
2. Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
Louis JA; Conceiçao-Silva F; Himmelrich H; Tacchini-Cottier F; Launois P
Adv Exp Med Biol; 1998; 452():53-60. PubMed ID: 9889959
[TBL] [Abstract][Full Text] [Related]
3. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
[TBL] [Abstract][Full Text] [Related]
4. The role of IL-12 in regulation of T helper cell subsets in vivo. Lessons from experimental cutaneous leishmaniasis.
Scott P; Hondowicz B; Eaton A; Scharton-Kersten T
Ann N Y Acad Sci; 1996 Oct; 795():250-6. PubMed ID: 8958936
[No Abstract] [Full Text] [Related]
5. New insight into the mechanisms underlying Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
Launois P; Himmelrich H; Tacchini-Cottier F; Milon G; Louis JA
Microbes Infect; 1999 Jan; 1(1):59-64. PubMed ID: 10847767
[No Abstract] [Full Text] [Related]
6. Acute IL-4 Governs Pathogenic T Cell Responses during
Poudel B; Yorek MS; Mazgaeen L; Brown SA; Kanneganti TD; Gurung P
Immunohorizons; 2020 Sep; 4(9):546-560. PubMed ID: 32948646
[No Abstract] [Full Text] [Related]
7. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses.
Arendse B; Van Snick J; Brombacher F
J Immunol; 2005 Feb; 174(4):2205-11. PubMed ID: 15699153
[TBL] [Abstract][Full Text] [Related]
8. Leishmania susceptibility puzzle gets another twist.
Marx J
Science; 1996 Feb; 271(5251):912-3. PubMed ID: 8584928
[No Abstract] [Full Text] [Related]
9. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.
Radwanska M; Cutler AJ; Hoving JC; Magez S; Holscher C; Bohms A; Arendse B; Kirsch R; Hunig T; Alexander J; Kaye P; Brombacher F
PLoS Pathog; 2007 May; 3(5):e68. PubMed ID: 17500591
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
[TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development.
Güler ML; Gorham JD; Hsieh CS; Mackey AJ; Steen RG; Dietrich WF; Murphy KM
Science; 1996 Feb; 271(5251):984-7. PubMed ID: 8584935
[TBL] [Abstract][Full Text] [Related]
12. KM(+), a lectin from Artocarpus integrifolia, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against Leishmania major antigens, resulting in BALB/c mice resistance to infection.
Panunto-Castelo A; Souza MA; Roque-Barreira MC; Silva JS
Glycobiology; 2001 Dec; 11(12):1035-42. PubMed ID: 11805076
[TBL] [Abstract][Full Text] [Related]
13. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells.
Aseffa A; Gumy A; Launois P; MacDonald HR; Louis JA; Tacchini-Cottier F
J Immunol; 2002 Sep; 169(6):3232-41. PubMed ID: 12218142
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to Leishmania major infection in interleukin-4-deficient mice.
Noben-Trauth N; Kropf P; Müller I
Science; 1996 Feb; 271(5251):987-90. PubMed ID: 8584936
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection.
Roberts MT; Stober CB; McKenzie AN; Blackwell JM
Infect Immun; 2005 Nov; 73(11):7620-8. PubMed ID: 16239566
[TBL] [Abstract][Full Text] [Related]
17. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
[TBL] [Abstract][Full Text] [Related]
18. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.
Titus RG; DeKrey GK; Morris RV; Soares MB
Infect Immun; 2001 Aug; 69(8):5189-92. PubMed ID: 11447205
[TBL] [Abstract][Full Text] [Related]
20. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response.
Chakir H; Campos-Neto A; Mojibian M; Webb JR
Microbes Infect; 2003 Apr; 5(4):241-9. PubMed ID: 12706437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
